C L A I M S

1. Use of electromagnetic signals generated by pulsating, impulse-modulated direct current, where the frequency is 1 to 30 Hz and the field strength 1 to 20 G for the treatment of osteoporosis.

2. Use according to claim 1, characterised in that the modulation form is quasi-rectangular.

3. Use according to claim 1 or 2, characterised in that the frequency is approximately 5 to 15 Hz.

4. Use according to claims 1 to 3, characterised in that the field strength is approximately 10 to 15 G.

5. Use according to claim 4, characterised in that the preferred field strength is approximately 12.5 G.

6. Use according to claims 1 to 5, characterised in that the pulses are modulated.

7. Use of Botulinum toxin for the preparation of a pharmaceutical composition for the treatment of osteoporosis in patients who are simulatenously exposed to electromagnetic signals generated by pulsating, pulse-modulated, unidirectional, direct current, with frequency between 1 and 30 Hz and field strength, 1 to 20 G.

8. Use according to claim 7, characterised in that the modulation form is quasi-rectangular.

9. Use according to claim 7 or 8, characterised in that the frequency is approximately 5 to 15 Hz.

10. Use according to claims 7 to 9, characterised in that the field strength is approximately 10 to 15 G.

11. Use according to claim 10, characterised in that the field strength is approximately 12.5 G

12. Use according to claims 7 to 11, characterised in that the pulses are modulated.

13. Use according to claims 7 to 12, characterized in that the dose of Botulinum toxin Type A used is in the range of 20U to 600U.

14. Use according to claims 13, characterized in that Botulinum toxin Type A used is in the range of 50U to 300U.

15. Use according to claims 7 to 12, characterized in that Botulinum toxin Type B used is in the range 1U to 20000U.